Monte Rosa Therapeutics, Inc.
GLUE
$4.59
-$0.23-4.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 394.01% | 7,882.05% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 394.01% | 7,882.05% | -- | -- | -- |
| Cost of Revenue | 13.16% | 20.85% | 44.34% | -3.08% | -- |
| Gross Profit | 72.10% | 329.82% | 193.78% | 38.09% | -- |
| SG&A Expenses | -16.85% | -2.83% | 15.83% | -3.88% | 43.27% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.78% | 13.56% | 36.66% | -3.31% | 0.31% |
| Operating Income | 52.35% | 226.01% | 137.30% | 28.24% | 12.30% |
| Income Before Tax | 63.08% | 249.62% | 146.89% | 31.47% | 14.09% |
| Income Tax Expenses | 375.79% | 890.36% | 9,936.36% | -58.24% | 32.63% |
| Earnings from Continuing Operations | 59.44% | 246.66% | 140.41% | 31.60% | 13.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 59.44% | 246.66% | 140.41% | 31.60% | 13.84% |
| EBIT | 52.35% | 226.01% | 137.30% | 28.24% | 12.30% |
| EBITDA | 56.09% | 239.44% | 145.63% | 30.48% | 14.65% |
| EPS Basic | 64.84% | 207.40% | 128.01% | 58.46% | 40.21% |
| Normalized Basic EPS | 67.99% | 209.42% | 132.49% | 58.37% | 40.43% |
| EPS Diluted | 65.12% | 207.26% | 128.01% | 58.46% | 39.57% |
| Normalized Diluted EPS | 67.99% | 208.36% | 132.49% | 58.37% | 40.43% |
| Average Basic Shares Outstanding | 15.38% | 36.56% | 44.25% | 64.63% | 44.11% |
| Average Diluted Shares Outstanding | 15.38% | 37.90% | 44.25% | 64.63% | 44.11% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |